title: Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.
abstract: To minimize the side effects and the multidrug resistance (MDR) arising from daunorubicin (DNR) treatment of malignant lymphoma, a chemotherapy formulation of cysteamine-modified cadmium tellurium (Cys-CdTe) quantum dots coloaded with DNR and gambogic acid (GA) nanoparticles (DNR-GA-Cys-CdTe NPs) was developed. The physical property, drug-loading efficiency and drug release behavior of these DNR-GA-Cys-CdTe NPs were evaluated, and their cytotoxicity was explored by 3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide assay. These DNR-GA-Cys-CdTe NPs possessed a pH-responsive behavior, and displayed a dose-dependent antiproliferative activity on multidrug-resistant lymphoma Raji/DNR cells. The accumulation of DNR inside the cells, revealed by flow cytometry assay, and the down-regulated expression of P-glycoprotein inside the Raji/DNR cells measured by Western blotting assay indicated that these DNR-GA-Cys-CdTe NPs could minimize the MDR of Raji/DNR cells. This multidrug delivery system would be a promising strategy for minimizing MDR against the lymphoma.
authors: Department of Hematology, Drum Tower Hospital, School of Medicine; Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing People's Republic of China.
authors: Yi
authors: Y
authors: Zhou
authors: Department of Hematology, Drum Tower Hospital, School of Medicine.
authors: Ruju
authors: R
authors: Wang
authors: Department of Hematology, Drum Tower Hospital, School of Medicine.
authors: Bing
authors: B
authors: Chen
authors: School of Mechanical Engineering, Queen's University Belfast, Belfast, UK.
authors: Dan
authors: D
authors: Sun
authors: Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing People's Republic of China.
authors: Yong
authors: Y
authors: Hu
authors: Department of Hematology, Drum Tower Hospital, School of Medicine.
authors: Peipei
authors: P
authors: Xu
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D019187:Cadmium Compounds / Q000737:chemistry*; D045744:Cell Line, Tumor; D003543:Cysteamine / Q000737:chemistry*; D003630:Daunorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D065546:Drug Liberation; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D051379:Mice; D045663:Quantum Dots / Q000737:chemistry*; D013691:Tellurium / Q000737:chemistry*; D044004:Xanthones / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D019187:Cadmium Compounds; D044004:Xanthones; D003543:Cysteamine; C052659:gambogic acid; D013691:Tellurium; C028337:cadmium telluride; D003630:Daunorubicin
keywords: Cys-CdTe QDs; daunorubicin; gambogic acid; multidrug resistance; non-Hodgkin’s lymphoma